RxDoctor Payments Data

Anthony Digioia, MD

Orthopaedic Surgery · Pittsburgh, PANPI 1992713259

Payments from drug & device makers

What this record shows

This record is dominated by other: $177,312 of the $217,447 with a category attached, or 81.5%. Smith+Nephew accounts for 81.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $180,312 and has fallen 94.5% since, to $9,990 in 2024. Among orthopaedic surgery clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$217,447in general payments, 2019–2025

Across 15 payments — averaging $14,496 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$177K
  • Zimmer Biomet$40K
  • CSL Behring$20
  • Solventum Corporation$15

What the payments were for

  • Speaking & faculty fees$40,10018%
  • Food & beverage$150%
  • Education$200%
  • Other$177,31282%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew1$177,312
Zimmer Biomet12$40,100
CSL Behring1$20
Solventum Corporation1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$217,447 in reported general payments places this provider in the 95th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.

See all orthopaedic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$179,615
Medicare patients
369
Services billed
2,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$6,775
Cephalexin67$1,071
Terazosin Hcl11$126
Celecoxib11$123
Oxycodone Hcl15$65
Tranexamic Acid12$49
Clindamycin Hcl12$30

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →